The European Medicines Agency Review of Cabazitaxel (Jevtana®) for the Treatment of Hormone-Refractory Metastatic Prostate Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

On March 17, 2011 the European Commission issued a marketing authorization valid throughout the European Union for Jevtana® (Sanofi-Aventis, Paris, France) for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. The act...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pean, Elias, Demolis, Pierre, Moreau, Alexandre, Hemmings, Robert James, O'Connor, Daniel, Brown, David, Shepard, Terry, Abadie, Eric, Pignatti, Francesco
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2012
Materias:
Regulatory Issues: EMA
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3336839/
https://ncbi.nlm.nih.gov/pubmed/22477727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0364
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares